TRiCares is a privately held medical-device company headquartered in Aschheim, Germany that focuses on minimally invasive treatment of tricuspid regurgitation (TR). Its flagship product, Topaz, is a transfemoral and transjugular tricuspid valve replacement system featuring a dual-stent design that avoids the need for high-risk open-heart surgery. The device is engineered to accommodate a wide range of patient anatomies and fully replaces the diseased tricuspid valve. Led by President and CEO Ahmed Elmouelhi, TRiCares maintains offices in France, Germany, the United States and Brazil to support product development and anticipated commercial expansion. The company plans to use newly raised capital to accelerate operations and further clinical and engineering work on Topaz. No operating metrics or previous revenue figures were disclosed in the article.

Total raised

$153M

Funding rounds

4

Latest round

Debt Financing

Latest activity

Jan 2026